OLIVIA GOFF BERRY: Open Payments
NPI 1942829817 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,569 in 79 payments from 12 companies in 2025. Trend: 2023 $1,637 · 2024 $690 · 2025 $1,569
Food & beverage: $1,569
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 30 | $481 |
| Novartis Pharmaceuticals Corporation | 14 | $331 |
| CSL Behring | 13 | $215 |
| Galderma Laboratories, L.P. | 4 | $117 |
| GENZYME CORPORATION | 4 | $112 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $93 |
| Optinose US, Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| Lilly USA, LLC | 1 | $33 |
Products named: NUCALA, Rhapsido, Hizentra, TRELEGY ELLIPTA, NEMLUVIO, DUPIXENT, NEFFY, XOLAIR.
Industry payments across AZ — which companies pay providers there.
